BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Major railway disruptions persist as Germany braces for more snow - 2Hungary's 'water guardian' farmers fight back against desertification
- 3Interpreter Starts Sobbing as 11-Year-Old Testifies About Last Time He Saw His Mom Before She Was Killed in Missile Strike
- 4The risk of falling space junk hitting airplanes is on the rise, experts warn
- 5Flu cases spiking this holiday season, CDC data shows
- The Delight of Camper Vans: Choosing the One That Meets Your Requirements
- 10 Delectable Specialty Mixed drinks
- Record-breaking flu hospitalizations in New York in a single week: Health officials
- The 10 Most Famous Works of art Ever
- The Hybrid Volkswagen ID. ERA 9X Will Become the Brand’s New Flagship in China
- The Most Compelling Innovation Developments Somewhat recently
- Make Your Fantasy Closet: 10 Immortal Design Fundamentals
- AfD in Brandenburg takes back suit against the intelligence service
- UN chief calls on Yemen's Houthi rebels to free all UN detainees
